ISRCTN20363887已完成未知
Valdoxan ImproVes depRession with anxiEty symptoms: a non-interventional study
Servier Deutschland GmbH (Germany)0 个研究点目标入组 3,000 人开始时间: 2012年6月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3,000
研究概览
简要总结
- 2015 results in DOI: 10.1055/s-0038-1627629 (added 18/01/2019) 2. 2016 results in DOI: 10.1055/s-0037-1616456 (added 18/01/2019)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Adult patients with episodes of major depression according to the SmPC
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
已完成
4 期
VIVALDI: Valdoxan® improves depressive symptoms and normalises circadian rhythmsEpisodes of major depressionMental and Behavioural DisordersDepressive episodeISRCTN49411996Servier Deutschland GmbH (Germany)8,000
已完成
4 期
VIVALDI Praxis: Valdoxan improves depressive symptoms and normalizes circadian rhythmsEpisodes of major depressionMental and Behavioural DisordersRecurrent depressive disorderISRCTN18801971Servier Deutschland GmbH (Germany)3,600
已完成
不适用
VIVID-ONValdoxan® improves vitality in depression with anhedoniaF32Depressive episodeDRKS00011602Servier Deutschland GmbH970
Unknown
不适用
Study of Vilazodone to Treat Social Anxiety DisorderSocial Anxiety DisorderNCT01712321The Medical Research Network30
已完成
不适用
Reducing symptoms of depression and anxiety in adolescents with inflammatory bowel disease in order to improve quality of life and the clinical course of diseaseangststoornissenInflammatory Bowel Disease (IBD) / Chronic bowel inflammation1001796910027946NL-OMON44382Erasmus MC, Universitair Medisch Centrum Rotterdam100